XML 44 R30.htm IDEA: XBRL DOCUMENT v3.6.0.2
Summary of Significant Accounting Policies (Details)
1 Months Ended 3 Months Ended 12 Months Ended 18 Months Ended
Aug. 31, 2015
USD ($)
May 31, 2014
USD ($)
Mar. 31, 2013
USD ($)
Dec. 31, 2011
USD ($)
Dec. 31, 2016
USD ($)
segment
item
Dec. 31, 2015
USD ($)
item
Dec. 31, 2014
USD ($)
Dec. 31, 2012
USD ($)
Mar. 31, 2013
Fair Value Measurements                  
Number Of Operating Segments | segment         1        
Assets measured at fair value levels 2 or 3         $ 0 $ 0      
Liabilities measured at fair value levels 2 or 3         0 0      
Carrying value of cash held in money market fund         $ 38,000,000 $ 45,500,000      
Impairment of Long-Lived Assets                  
Number of long-lived assets determined to be impaired | item         0 0      
Assets held for sale         $ 0 $ 0      
Share-based Compensation                  
Expected term         6 years 3 months        
Maximum                  
Share-based Compensation                  
Expected term         10 years        
Pfizer | License Agreement                  
Revenue Recognition                  
Milestone revenue $ 20,000,000 $ 15,000,000     $ 0 $ 20,000,000 $ 15,000,000    
Number of milestones met | item         0        
Pfizer | License Agreement | Up-Front Payment Arrangement                  
Revenue Recognition                  
Upfront payment revenue recognized     $ 22,500,000 $ 22,500,000       $ 22,500,000  
Recognition period of up-front payment                 1 year 6 months